Further, systemic administration of a CD88 antagonist has been reported to decrease the pathology, increase synaptophysin immunolabelling in the CA3 stratum lucidum and enhance behavioural outcomes in mouse models of Alzheimer's disease [6]. The gene discussed is SYP; the disease is early-onset autosomal dominant Alzheimer disease.